FC
ZNTL icon

FORA Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

FORA Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,692
Closed -$143K – 904
2021
Q2 		$143K Buy
+2,692
New +$144K 0.03% 512
2021
Q1 		– Sell
-4,234
Closed -$220K – 1158
2020
Q4 		$220K Buy
+4,234
New +$191K 0.03% 498

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's ZNTL Position: Q3 2021 in Review

FORA Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2021, closing a stake of 2,692 shares — an estimated $143K sold.

FORA Capital first reported a position in ZNTL in Q4 2020 and held it in 2 quarters. The position peaked at $220K in Q4 2020. 116 funds tracked by Wall St. Rank hold ZNTL as of Q3 2021.

  • FORA Capital reported no remaining Zentalis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • FORA Capital sold 2,692 Zentalis Pharmaceuticals shares in Q3 2021, an estimated $143K.
  • FORA Capital first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • FORA Capital's Zentalis Pharmaceuticals position peaked at $220K in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.